| 2026-01-21 | +75.7% | expansion | Seeking Alpha | PAVmed-subsidiary Lucid Diagnostics spikes on Veterans Affairs contract |
| 2026-01-21 | +75.7% | news | Benzinga | Why Is PAVmed Stock Skyrocketing Wednesday? - Benzinga |
| 2026-01-21 | +75.7% | expansion | Seeking Alpha | PAVmed-subsidiary Lucid Diagnostics spikes on Veterans Affairs contract - Seeking Alpha |
| 2026-01-21 | +75.7% | news | timothysykes.com | PAVmed Shares Soar Amid Strategic Developments and Market Reactions - timothysykes.com |
| 2026-01-21 | +75.7% | M&A | Stocktwits | PAVM Stock Shot Up Over 250% Today – What’s The Deal With The Department of Veterans Affairs? - Stocktwits |
| 2026-01-21 | +75.7% | news | TipRanks | Why Are PAVmed (PAVM) & Lucid Diagnostics (LUCD) Stocks Up Today? - TipRanks |
| 2026-01-21 | +75.7% | news | Invezz | Should you chase the rally in PAVmed stock after it quadrupled on Wednesday? - Invezz |
| 2023-08-30 | +36.4% | news | Yahoo Finance | Here's Why PAVmed Inc. (PAVM) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance |
| 2026-01-15 | -28.6% | analyst | MSN | PAVmed (PAVM) price target increased by 2,900.00% to 321.30 - MSN |
| 2022-08-17 | -26.9% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-01-18 | -25.2% | legal | SEC EDGAR | PAVM 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-12-30 | -21.0% | news | Seeking Alpha | PAVmed announces 1-for-30 reverse stock split |
| 2025-12-30 | -21.0% | news | PR Newswire | PAVmed Announces Reverse Stock Split - PR Newswire |
| 2025-12-30 | -21.0% | news | Stock Titan | 1-for-30 reverse split aims to keep PAVmed shares on Nasdaq exchange - Stock Titan |
| 2022-11-15 | -20.5% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-06-28 | +18.1% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2024-11-29 | +17.3% | legal | SEC EDGAR | PAVM 8-K: 1.01, 2.03, 3.03 (SEC Filing) |
| 2021-11-16 | -16.7% | news | Business Wire | PAVmed and Lucid Provide Business Update and Preliminary Third Quarter 2021 Financial Results - Business Wire |
| 2023-12-04 | -16.1% | news | PR Newswire | PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split - PR Newswire |
| 2025-11-13 | -15.6% | earnings | Seeking Alpha | PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript |
| 2025-11-13 | -15.6% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-11-13 | -15.6% | news | PR Newswire | PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results - PR Newswire |
| 2025-11-13 | -15.6% | earnings | Yahoo Finance | PAVmed Inc (PAVM) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... - Yahoo Finance |
| 2026-01-23 | -15.5% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2025-11-11 | +15.2% | earnings | Seeking Alpha | PAVmed Q3 2025 Earnings Preview |
| 2025-10-10 | +14.7% | analyst | Yahoo Finance | PAVmed (PAVM) Upgraded to Strong Buy: Here's Why - Yahoo Finance |
| 2026-03-30 | +14.5% | earnings | GuruFocus.com | PAVmed Inc (PAVM) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Growth Initiatives |
| 2026-03-30 | +14.5% | analyst | Zacks | PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know |
| 2026-03-30 | +14.5% | news | PR Newswire | PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-30 | +14.5% | earnings | Seeking Alpha | PAVmed Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-03-30 | +14.5% | earnings | Seeking Alpha | PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript |
| 2026-03-30 | +14.5% | earnings | Seeking Alpha | PAVmed Non-GAAP EPS of -$1.05 |
| 2026-03-30 | +14.5% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2026-03-30 | +14.5% | analyst | Yahoo Finance | PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know - Yahoo Finance |
| 2026-03-30 | +14.5% | news | PR Newswire | PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire |
| 2026-03-30 | +14.5% | earnings | Seeking Alpha | PAVmed Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:PAVM) 2026-03-30 - Seeking Alpha |
| 2026-03-30 | +14.5% | news | bitget.com | PAVmed (PAVM) Raised to Buy: Key Information You Need - bitget.com |
| 2024-11-14 | +13.7% | earnings | Seeking Alpha | PAVmed Inc. (PAVM) Q3 2024 Earnings Call Transcript |
| 2024-11-14 | +13.7% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-05-14 | -13.5% | earnings | Seeking Alpha | PAVmed Q1 2025 Earnings Preview |
| 2026-02-04 | +12.3% | legal | SEC EDGAR | PAVM 8-K: 1.01, 1.02, 2.03, 3.02, 3.03, 5.03, 7.01 (SEC Filing) |
| 2026-02-04 | +12.3% | legal | PR Newswire | PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities - PR Newswire |
| 2026-02-04 | +12.3% | expansion | TradingView | PAVmed Signs Multiple Financing Agreements - TradingView |
| 2025-05-15 | -12.2% | earnings | Seeking Alpha | PAVmed Inc. (PAVM) Q1 2025 Earnings Call Transcript |
| 2025-05-15 | -12.2% | earnings | Seeking Alpha | PAVmed Non-GAAP EPS of -$0.07 beats by $0.22, revenue of $0.08M beats by $0.07M |
| 2025-05-15 | -12.2% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2021-08-12 | -12.0% | legal | SEC EDGAR | PAVM 8-K: 2.02 and (SEC Filing) |
| 2024-08-13 | -12.0% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-10-11 | +12.0% | news | TradingKey | PAVM|PAVmed Inc|Price:9.170|Chg%:-0.20 - TradingKey |
| 2022-02-24 | +11.7% | legal | SEC EDGAR | PAVM 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-03-27 | +11.7% | analyst | Seeking Alpha | PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript |
| 2026-03-27 | +11.7% | legal | SEC EDGAR | PAVM 8-K: 5.02, 5.03, 5.07 (SEC Filing) |
| 2026-03-27 | +11.7% | news | Stock Titan | PAVmed (NASDAQ: PAVM) holders approve stock issuances and expand equity plan - Stock Titan |
| 2023-03-15 | -11.5% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-02-09 | +11.4% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2022-05-12 | -11.1% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-04-04 | -10.8% | legal | SEC EDGAR | PAVM 8-K: 1.01, 2.03, 7.01 (SEC Filing) |
| 2025-01-21 | -10.7% | legal | SEC EDGAR | PAVM 8-K: 3.01, 3.02, 3.03, 5.03, 8.01 (SEC Filing) |
| 2024-03-14 | -10.4% | legal | SEC EDGAR | PAVM 8-K: 1.01, 3.03 (SEC Filing) |
| 2025-11-14 | +9.4% | earnings | Seeking Alpha | PAVmed Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2022-03-03 | -8.8% | legal | SEC EDGAR | PAVM 8-K: 1.01, 2.01 (SEC Filing) |
| 2021-06-16 | +8.3% | legal | SEC EDGAR | PAVM 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-03-24 | -8.2% | earnings | Seeking Alpha | PAVmed Q4 2024 Earnings Preview |
| 2024-02-12 | +7.5% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2022-03-29 | -7.1% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-01-24 | +6.9% | legal | SEC EDGAR | PAVM 8-K: 3.01, 3.02, 3.03 (SEC Filing) |
| 2024-01-08 | -6.8% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2025-04-08 | +6.7% | news | Seeking Alpha | AVmed files to sell 3.3M shares of common stock for holders |
| 2026-04-09 | -6.6% | news | PR Newswire | Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference |
| 2026-04-09 | -6.6% | analyst | Simply Wall St. | How The PAVmed (PAVM) Narrative Is Shifting After The Latest Analyst Reassessment |
| 2026-04-09 | -6.6% | executive | Stock Titan | PAVmed (PAVM) CEO Aklog reports 5.1% stake and 350,000 restricted shares - Stock Titan |
| 2026-04-09 | -6.6% | news | TradingView | Lishan Aklog Discloses Investment at PAVmed Inc. with 5.1% Stake - TradingView |
| 2023-02-17 | -6.4% | legal | SEC EDGAR | PAVM 8-K: 1.02, 8.01 (SEC Filing) |
| 2022-08-26 | -5.9% | analyst | TradingView | PAVM Forecast — Price Target — Prediction for 2027 - TradingView |
| 2021-06-02 | +5.9% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2021-05-17 | +5.8% | legal | SEC EDGAR | PAVM 8-K: 2.02 and (SEC Filing) |
| 2022-04-01 | -5.7% | legal | SEC EDGAR | PAVM 8-K: 1.01 and (SEC Filing) |
| 2025-02-21 | +5.1% | legal | SEC EDGAR | PAVM 8-K: 3.02 and (SEC Filing) |
| 2024-04-26 | -4.7% | legal | SEC EDGAR | PAVM 8-K: 1.01 and (SEC Filing) |
| 2025-06-18 | -4.7% | legal | SEC EDGAR | PAVM 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-04-07 | -4.6% | expansion | Zacks | PAVM Assigns Joseph Virgilio to Lead Medical Device Portfolio Relaunch |
| 2025-03-10 | -4.6% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2026-04-23 | -4.3% | news | PR Newswire | Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock |
| 2026-04-23 | -4.3% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | PAVmed Inc. (PAVM) posts narrow Q4 2025 EPS miss, shares edge higher in muted investor trading. - Community Exit Signals - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-23 | -4.3% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | PAVmed Inc. (PAVM) posts narrow Q4 2025 EPS miss, shares edge higher in muted investor trading. - Viral Trade Signals - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-04-24 | -4.1% | news | Seeking Alpha | PAVmed, Lucid post encouraging results from EsoGuard study |
| 2025-04-24 | -4.1% | news | Stock Titan | Pavmed Stock Price, News & Analysis - Stock Titan |
| 2026-04-06 | -4.0% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | Will PAVmed (PAVM) Stock Miss Expectations | Price at $9.97, Up 1.27% - Community Exit Signals - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-06 | -4.0% | news | Stock Titan | Tasso Partners, LLC (PAVM) reports large PAVmed stake and warrant position - Stock Titan |
| 2026-04-06 | -4.0% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | Will PAVmed (PAVM) Stock Miss Expectations | Price at $9.97, Up 1.27% - Social Trading Insights - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-07-16 | +3.8% | news | Seeking Alpha | Lucid says meeting scheduled to determine Medicare coverage for cancer test |
| 2024-11-21 | -3.8% | legal | SEC EDGAR | PAVM 8-K: 1.01, 3.02, 3.03 (SEC Filing) |
| 2026-04-18 | +3.7% | news | Cổng thông tin điện tử tỉnh Tây Ninh | PAVmed (PAVM) Stock Resistance Rejection (+0.11%) 2026-04-18 - Fundamental Analysis - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2024-09-16 | -3.3% | legal | SEC EDGAR | PAVM 8-K: 2.01, 3.01, 5.02, 7.01 (SEC Filing) |
| 2024-01-30 | -3.2% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2025-04-11 | +3.1% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2026-04-13 | -3.1% | news | Stock Titan | [Form 3] PAVmed Inc. Initial Statement of Beneficial Ownership - Stock Titan |
| 2026-04-13 | -3.1% | news | Stock Titan | 70,000-share PAVmed (PAVM) restricted stock grant to CMO - Stock Titan |
| 2026-04-13 | -3.1% | news | Stock Titan | Scopia Holdings/Member Matthew Sirovich reports 9.99% in PAVmed (PAVM) - Stock Titan |
| 2021-06-14 | +2.8% | legal | SEC EDGAR | PAVM 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-03-25 | +2.8% | earnings | Seeking Alpha | PAVmed outlines strategic milestones for 2025, including Veris implantable device submission |
| 2025-03-25 | +2.8% | earnings | Seeking Alpha | PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript |
| 2025-03-25 | +2.8% | earnings | Seeking Alpha | PAVmed Inc. 2024 Q4 - Results - Earnings Call Presentation |
| 2025-03-25 | +2.8% | earnings | Seeking Alpha | PAVmed Non-GAAP EPS of -$0.06 beats by $0.34, revenue of $0.01M misses by $0.01M |
| 2025-03-25 | +2.8% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-08-13 | +2.8% | earnings | Seeking Alpha | PAVmed Q2 2025 Earnings Preview |
| 2025-03-21 | +2.8% | earnings | Seeking Alpha | PAVmed Q4 2024 Earnings Preview |
| 2025-11-12 | +2.7% | earnings | Seeking Alpha | PAVmed Q3 2025 Earnings Preview |
| 2025-11-12 | +2.7% | earnings | Seeking Alpha | PAVmed Non-GAAP EPS of -$0.10, revenue of $1.21M |
| 2025-11-12 | +2.7% | earnings | Yahoo Finance | PAVmed Inc (PAVM) Q3 2025 Earnings Report Preview: What to Expect - Yahoo Finance |
| 2024-05-14 | -2.7% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2023-03-14 | +2.6% | legal | SEC EDGAR | PAVM 8-K: 1.01, 2.03, 3.03 (SEC Filing) |
| 2026-04-02 | -2.5% | expansion | PR Newswire | PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio |
| 2025-03-26 | +2.5% | news | Intellectia AI | PAVM Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2023-10-18 | -2.5% | legal | SEC EDGAR | PAVM 8-K: 1.01, 3.03 (SEC Filing) |
| 2023-06-06 | +2.4% | legal | SEC EDGAR | PAVM 8-K: 3.02 and (SEC Filing) |
| 2025-02-24 | -2.3% | news | PR Newswire | PAVmed and Subsidiary Veris Health Complete Private Placement Financing - PR Newswire |
| 2022-12-02 | -2.2% | legal | SEC EDGAR | PAVM 8-K: 8.01 (SEC Filing) |
| 2025-08-14 | -1.9% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-12-05 | +1.9% | analyst | Seeking Alpha | PAVmed Inc. (PAVM) Shareholder/Analyst Call Prepared Remarks Transcript |
| 2026-03-25 | -1.6% | earnings | Seeking Alpha | PAVmed Q4 2025 Earnings Preview |
| 2025-09-11 | -1.5% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2026-04-14 | -1.5% | news | Stock Titan | Dana Carrera, Tasso Partners disclose 15.3% stake in PAVmed (NASDAQ: PAVM) - Stock Titan |
| 2026-04-03 | +1.5% | news | Stock Titan | PAVmed (PAVM) director gets 13,930-share restricted stock grant - Stock Titan |
| 2026-04-03 | +1.5% | executive | Stock Titan | PAVmed (PAVM) COO receives 110,000-share restricted stock grant vesting 2029 - Stock Titan |
| 2026-04-03 | +1.5% | news | Stock Titan | Director at PAVmed (PAVM) receives 13,930 restricted stock shares - Stock Titan |
| 2026-04-03 | +1.5% | executive | Stock Titan | PAVmed (PAVM) CFO awarded 180,000 restricted shares vesting 2029 - Stock Titan |
| 2026-04-03 | +1.5% | news | Stock Titan | PAVmed (PAVM) general counsel receives 110,000-share restricted award - Stock Titan |
| 2026-04-03 | +1.5% | news | Stock Titan | Restricted stock award boosts PAVmed (NASDAQ: PAVM) director stake - Stock Titan |
| 2026-04-03 | +1.5% | news | Stock Titan | Restricted stock grant boosts PAVmed (PAVM) director’s holdings - Stock Titan |
| 2026-04-03 | +1.5% | news | Stock Titan | Craig Kallman (PAVM) holds 384,616 shares, a 6.0% stake in PAVmed - Stock Titan |
| 2026-04-03 | +1.5% | executive | Stock Titan | PAVmed (PAVM) CEO Lishan Aklog awarded 350,000 restricted shares vesting 2029 - Stock Titan |
| 2026-04-03 | +1.5% | news | Stock Titan | Tasso Partners and Dana Carrera disclose 14.3% stake in PAVmed (PAVM) - Stock Titan |
| 2026-04-03 | +1.5% | news | Stock Titan | PAVmed (PAVM) director Timothy Baxter receives 13,930 restricted shares vesting in 2029 - Stock Titan |
| 2025-04-17 | -1.4% | legal | SEC EDGAR | PAVM 8-K: 1.01 and (SEC Filing) |
| 2025-11-18 | +1.2% | news | simplywall.st | Is PAVmed (NASDAQ:PAVM) Using Debt Sensibly? - simplywall.st |
| 2026-04-21 | -1.1% | news | Stock Titan | PAVmed (NASDAQ: PAVM) registers 9.23M common shares; $30M potential from warrants - Stock Titan |
| 2025-06-24 | -0.8% | legal | SEC EDGAR | PAVM 8-K: 1.01 and (SEC Filing) |
| 2025-06-24 | -0.8% | news | PR Newswire | PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing - PR Newswire |
| 2021-11-04 | +0.8% | legal | SEC EDGAR | PAVM 8-K: 2.02 and (SEC Filing) |
| 2025-08-12 | +0.8% | earnings | Seeking Alpha | PAVmed Q2 2025 Earnings Preview |
| 2026-03-31 | +0.8% | earnings | Moby | PAVmed Inc. Q4 2025 Earnings Call Summary |
| 2021-10-07 | +0.7% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2026-04-08 | -0.7% | news | Stock Titan | PAVmed (NASDAQ: PAVM) Scott Dols reports 5.4% stake, 346,155 shares - Stock Titan |
| 2026-04-08 | -0.7% | news | Stock Titan | Nagelberg disclosures show 8.6% ownership in PAVmed (NASDAQ: PAVM) - Stock Titan |
| 2025-01-25 | +0.6% | news | Investing.com | PAVMed faces Nasdaq delisting over share price rule - Investing.com |
| 2026-03-16 | +0.6% | earnings | Stock Titan | PAVmed executives to outline 2025 strategy, Q4 results on March 30 call - Stock Titan |
| 2025-05-26 | -0.5% | news | Intellectia AI | PAVM Forecast — Price Prediction for 2026. Should I Buy PAVM? - Intellectia AI |
| 2024-02-16 | +0.5% | legal | SEC EDGAR | PAVM 8-K: 2.01, 3.03, 8.01 (SEC Filing) |
| 2025-02-18 | -0.5% | news | Seeking Alpha | PAVmed regains Nasdaq compliance |
| 2025-02-18 | -0.5% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2023-03-13 | +0.5% | legal | SEC EDGAR | PAVM 8-K: 1.01, 3.03 (SEC Filing) |
| 2026-01-04 | -0.4% | news | citybiz | PAVmed Announces Reverse Stock Split - citybiz |
| 2021-04-27 | -0.4% | legal | SEC EDGAR | PAVM 8-K: 5.02 (SEC Filing) |
| 2024-05-07 | +0.3% | legal | SEC EDGAR | PAVM 8-K: 1.01, 3.03 (SEC Filing) |
| 2023-11-15 | -0.3% | legal | SEC EDGAR | PAVM 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-07-30 | +0.3% | news | Seeking Alpha | PAVmed gets 180-day extension to regain Nasdaq listing compliance |
| 2025-07-30 | +0.3% | legal | SEC EDGAR | PAVM 8-K: 8.01 and (SEC Filing) |
| 2025-07-30 | +0.3% | news | PR Newswire | PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PR Newswire |
| 2022-09-08 | +0.3% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for PAVmed (PAVM) - Zacks Investment Research |
| 2023-03-24 | +0.3% | legal | SEC EDGAR | PAVM 8-K: 1.01, 2.03, 3.03 (SEC Filing) |
| 2021-10-18 | -0.1% | legal | SEC EDGAR | PAVM 8-K: 2.01 (SEC Filing) |
| 2022-02-15 | +0.1% | legal | SEC EDGAR | PAVM 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-24 | — | news | PR Newswire | Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock |